Ert Pompe denied as experimental or investigational by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Pompe Disease ERT as Experimental — and Why That Denial Is Wrong

An "experimental or investigational" denial for enzyme replacement therapy for Pompe disease is among the most aggressively appealable denials in rare-disease medicine. ERT for Pompe disease has been FDA-approved for use in this indication, and FDA approval is the foundational threshold distinguishing established treatment from experimental treatment. Humana's own medical policies generally define "experimental" to exclude treatments with FDA approval for the indication being treated and adequate support in peer-reviewed medical literature.

If Humana is applying an experimental denial to an FDA-approved ERT for Pompe disease, the appeal argument is straightforward: the therapy has cleared the regulatory standard that the policy itself establishes as the boundary of experimental status.

## Federal Appeal Rights

Under ACA Section 2719, adverse benefit determinations based on an experimental or investigational classification are specifically subject to independent external review, even under plans that might otherwise limit external review. ERISA Section 503 guarantees a full-and-fair review process for covered participants. The external review window is approximately four months from the final internal denial. Expedited review is available when standard timelines would seriously jeopardize health — a standard that Pompe disease's progressive respiratory and motor deterioration can frequently satisfy.

## What to Gather

• FDA approval documentation — the FDA product label and the FDA's approval page for the specific ERT product, showing the approved indication matches the patient's diagnosis.
• Diagnosis confirmation — enzyme-activity assay, genetic testing, or biopsy results establishing the Pompe diagnosis.
• Humana's experimental-or-investigational policy — obtain the current version and locate the definition of "experimental," including what the policy says about FDA-approved therapies.
• Prescriber medical-necessity letter — the treating physician should state the diagnosis, the FDA-approved status of the requested therapy, and the clinical rationale for prescribing it.
• Published clinical practice guideline reference — cite the relevant professional organization's guideline for management of Pompe disease (without quoting specific statistics) to demonstrate that ERT is the recognized standard of care.

## Criteria-Mapping Structure

Build a table: left column lists each element of Humana's experimental definition; right column rebuts each element with the corresponding documentation. The FDA approval letter and label are usually sufficient to defeat every element of the experimental definition. If Humana cites a specific criterion the product allegedly fails, address it directly in the criteria table.

## Process and Timeline

1. File the written internal appeal promptly, within the plan's stated deadline. 2. Attach the FDA label, diagnosis documentation, and prescriber letter. 3. If Humana upholds the experimental classification internally, escalate immediately to external review — this category of denial is specifically covered by ACA external review protections. 4. Assess the expedited pathway given the progressive nature of untreated Pompe disease.